NASDAQ:NBRV
Delisted
Nabriva Therapeutics AG Stock News
$1.42
+0 (+0%)
At Close: Nov 24, 2023
Nabriva Therapeutics to Report Second Quarter 2021 Financial Results and Recent Corporate Highlights on August 5, 2021
07:01am, Thursday, 22'nd Jul 2021
DUBLIN, Ireland, July 22, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective ag
Down 15.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Nabriva Therapeutics AG (NBRV)
11:36am, Wednesday, 14'th Jul 2021
Nabriva Therapeutics AG (NBRV) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earn
Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 09'th Jul 2021
DUBLIN, Ireland, July 09, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective ag
Nabriva Agrees to Extension of Principal Debt Repayments Under Existing Loan Agreement with Hercules Capital
07:01am, Thursday, 03'rd Jun 2021
- Principal Repayments Delayed At Least Until January 1, 2022
Nabriva Announces Changes to its Board of Directors
06:02pm, Wednesday, 02'nd Jun 2021
DUBLIN, Ireland and FORT WASHINGTON, Pa., June 02, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of inn
Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:01am, Tuesday, 01'st Jun 2021
DUBLIN, Ireland, June 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective ag
Why Nabriva Therapeutics Stock Is Surging Today
09:17am, Wednesday, 26'th May 2021
Nabriva Therapeutics PLC – ADR (NASDAQ:NBRV) shares are trading higher by 48% at $2.19 Wednesday morning after the company, and Sinovant Sciences, announced topline results from the Phase 3 trial of
NBRV Stock Price: Over 60% Increase Pre-Market Explanation
05:45am, Wednesday, 26'th May 2021
The stock price of Nabriva Therapeutics PLC (NASDAQ: NBRV) increased by over 60% pre-market. This is why it happened.
HONG KONG, SHANGHAI, China, SUZHOU, China and DUBLIN, Ireland, May 25, 2021 (GLOBE NEWSWIRE) -- Sinovant Sciences, a Chinese biopharmaceutical company dedicated to conducting innovative biomedical R&D
Nabriva Therapeutics to Present at the Jefferies Virtual Healthcare Conference
07:01am, Friday, 21'st May 2021
DUBLIN, Ireland and KING OF PRUSSIA, Pa., May 21, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of inno
Nabriva Therapeutics plc (NBRV) CEO Ted Schroeder on Q1 2021 Results - Earnings Call Transcript
09:48am, Sunday, 09'th May 2021
Nabriva Therapeutics plc (NBRV) CEO Ted Schroeder on Q1 2021 Results - Earnings Call Transcript
Nabriva Therapeutics to Report First Quarter 2021 Financial Results and Recent Corporate Highlights on May 6, 2021
04:05pm, Thursday, 29'th Apr 2021
DUBLIN, Ireland, April 29, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective a
Rising P/E: An Overlooked Way to Pick 5 Winning Stocks
06:46am, Thursday, 29'th Apr 2021
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
Nabriva Commences Exclusive Distribution of SIVEXTRO® (tedizolid phosphate) in the U.S.
12:12pm, Thursday, 15'th Apr 2021
- SIVEXTRO now available under Nabriva's National Drug Code
Rising P/E: An Overlooked Strategy to Pick Winning Stocks
07:39am, Wednesday, 14'th Apr 2021
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
